The MMRF CureCloud Research Initiative, a novel direct-to-patient observational study developed by the Multiple Myeloma Research Foundation (MMRF), collects and aggregates de-identified genomic and clinical data from thousands of patients, providing each participant with a personalized genomic report based on their disease subtype, with the ultimate goal to individualize and optimize their treatment.
In the process, the initiative will create a data set that can inform treatment decisions for all patients with multiple myeloma (MM), according to Anne Quinn Young, MPH, brand president, MMRF. Gathering, aggregating, and sharing the data will lead to “democratization of care,” which is especially important in MM because it disproportionately affects underserved groups, Young said in an interview.
